Dabigatran etexilate (PRADAXA): new update information

date: 08 June 2012

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency continues to regularly evaluate all available data concerning the risk of serious bleeding following administration of Pradaxa. The benefit of this anticoagulant medicine continues to outweigh the risks, but the CHMP considers it necessary to give clearer recommendations for prescribers and patients to better control the risk of bleeding associated with the administration of this medicine.

 

See "Press release EMAExternal link"

 

Contact
vig@fagg-afmps.be

Last updated on 11 June 2012

5-year celebrations at famhp!

On this occasion the famhp has adopted a new visual identity and a new logo.

read more

PIL and SPC
of a medicine

(PIL: patient information leaflet SPC: summary of product characteristics)

Newsletter

Subscribe to our newsletter

Your e-mail